Results 141 to 150 of about 15,436 (169)

Scintigraphic Characterization of Amyloid Cardiomyopathy

Clinical Nuclear Medicine, 1985
Amyloidosis is an important entity in the differential diagnosis of cardiac failure of undetermined etiology. In this case report, the typical pattern of combined systolic and diastolic impairment in amyloid cardiomyopathy was demonstrated by analysis of the cardiac blood pool study.
C K, Li, M A, Rabinovitch, J E, Juni, J H, Thrall, B, Pitt, S K, Das, G D, Abrams, M, Helvie   +7 more
openaire   +2 more sources

Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy

American Journal of Therapeutics, 2021
Background: Deposition of wild-type or mutant transthyretin (TTR) amyloid fibrils in the myocardium causes TTR amyloid cardiomyopathy (ATTR-CM). Targeted therapeutics for ATTR-CM include TTR stabilizers (tafamidis and diflunisal) and oligonucleotide drugs (revusiran, patisiran, and inotersen).
Courtney M, Campbell, Cyril Ayuk Mbeng Takem, Baiyee, Salem, Almaani, Naresh, Bumma, Nidhi, Sharma, Samantha, LoRusso, Elyse, Redder, Jordan, Bittengle, Katherine, Pfund, Miriam, Friemer, Matthew, Tong, Rami, Kahwash, Yvonne, Efebera, Samir, Parikh, Ajay, Vallakati   +14 more
openaire   +2 more sources

Echocardiographic Findings in Amyloid Cardiomyopathy

Southern Medical Journal, 1978
Echocardiographic manifestations of two patients with cardiac amyloidosis are presented. The findings consisted of increased thickness of the left ventricular posterior wall and interventricular septal wall, a normal to small left ventricular cavity, and pericardial effusion.
T D, Giles, J, León-Galindo, G E, Burch
openaire   +2 more sources

Aging, Amyloid, and Cardiomyopathy

New England Journal of Medicine, 1997
In past decades, rheumatic heart disease, syphilitic heart disease, hypertensive heart disease, and even nutritional deficiencies were common enough for physicians to consider these diagnoses in pa...
openaire   +2 more sources

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

Circulation: Heart Failure, 2022
Benjamin Li, Scott L Hummel
exaly  

Expert Consensus on the Monitoring of Transthyretin Amyloid Cardiomyopathy

European Journal of Heart Failure, 2021
Laura Obici, Pablo Garcia-Pavia, Jose Nativi-Nicolau   +2 more
exaly  

Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy

Mayo Clinic Proceedings, 2022
Eduardo Barge-Caballero, Alfonso Varela-Román, Eva González-Babarro   +2 more
exaly  

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges

Journal of Clinical Medicine, 2022
Carsten Tschöpe, Ahmed Elsanhoury
exaly  

Echocardiogram for Amyloid Cardiomyopathy

New England Journal of Medicine, 1976
J S, Child, J A, Levisman, R N, MacAlpin, A S, Abbasi   +3 more
openaire   +3 more sources

Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT

JACC: Heart Failure, 2021
Mathew S Maurer, Kurt Boman, John L Berk
exaly